ConductScience.org, home

Paper32150618

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Yao X and 14 others. Clin Infect Dis, 2020. Cited by 1,665 papers, by iCite.

Cite this record

ConductScience Library. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Papers, record 32150618. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32150618

Download JSON
Disease
COVID-19540 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
PubMed
Journal
Clin Infect Dis
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
1,665
iCite
Relative citation ratio, by iCite
95.9
iCite
Revised in PubMed
2022-12-07
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yao XXueting
2Ye FFei
3Zhang MMiao
4Cui CCheng
5Huang BBaoying
6Niu PPeihua
7Liu XXu
8Zhao LLi
9Dong EErdan
10Song CChunli
11Zhan SSiyan
12Lu RRoujian
13Li HHaiyan
14Tan WWenjie
15Liu DDongyang

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
BetacoronavirusMajor topic
Coronavirus InfectionsMajor topic
HydroxychloroquineMajor topic
Pneumonia, ViralMajor topic
Severe Acute Respiratory SyndromeMajor topic
Animals
COVID-19
Cell Line
Chlorocebus aethiops
Chloroquine
Lung
Pandemics
SARS-CoV-2
Vero Cells
COVID-19 Drug Treatment

Source PubMed

Download CSV of topics

Trials17

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04334967Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of CareBackgroundClinicalTrials.gov
NCT04339816Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled TrialBackgroundClinicalTrials.gov
NCT04340349Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare ProfessionalsResultsClinicalTrials.gov
NCT04341441Will Hydroxychloroquine Impede or Prevent COVID-19BackgroundClinicalTrials.gov
NCT04345289Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 PneumoniaBackgroundClinicalTrials.gov
NCT04353271Trial of Hydroxychloroquine In Covid-19 KineticsBackgroundClinicalTrials.gov
NCT04354441Effect of Hydroxychloroquine in COVID-19 Positive Pregnant WomenBackgroundClinicalTrials.gov
NCT04359095Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in ColombiaResultsClinicalTrials.gov
NCT04361318Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19BackgroundClinicalTrials.gov
NCT04369989Observational Study of COVID-19 Treatment EfficacyBackgroundClinicalTrials.gov
NCT04370782Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient SettingBackgroundClinicalTrials.gov
NCT04380870Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19BackgroundClinicalTrials.gov
NCT04394416Trial of Imatinib for Hospitalized Adults With COVID-19BackgroundClinicalTrials.gov
NCT04434144A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in BangladeshBackgroundClinicalTrials.gov
NCT04491994Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 ProgressionBackgroundClinicalTrials.gov
NCT04627467Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)ResultsClinicalTrials.gov
NCT04654416Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and ColchicineBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections9

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in32211764Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019?https://conductscience.org/library/papers/32211764PubMed
Comment in32211771Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?https://conductscience.org/library/papers/32211771PubMed
Comment in32215614Hydroxychloroquine and Chloroquine.https://conductscience.org/library/papers/32215614PubMed
Comment in32241791To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic.https://conductscience.org/library/papers/32241791PubMed
Comment in32268005Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection.https://conductscience.org/library/papers/32268005PubMed
Comment in32607540Simulation of Drug in the Lung Can Be Misleading.https://conductscience.org/library/papers/32607540PubMed
Comment in32613227Reply to Wolowich and Kwon.https://conductscience.org/library/papers/32613227PubMed
Comment in33170206Response to Jia and Wang.https://conductscience.org/library/papers/33170206PubMed
Comment in33258095Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion.https://conductscience.org/library/papers/33258095PubMed

Download CSV of comments and corrections

Cited by1,394

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,665 citations.

PMIDTitleJournalYearIn PapersSource
42634088Pediatric Use of Off-Label Medicines and Nonevidence-Based Supplements for COVID-19: Findings From the 2015 Pelotas Birth Cohort Study (Brazil).Pharmacoepidemiol Drug Saf2026https://conductscience.org/library/papers/42634088PubMed
42515655Drug Repurposing as a Broad-Spectrum Strategy Against Coronaviruses: Frontiers in Mechanisms and Clinical Translation.Viruses2026https://conductscience.org/library/papers/42515655PubMed
42400597Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling.CPT Pharmacometrics Syst Pharmacol2026https://conductscience.org/library/papers/42400597PubMed
41708603cGAS-IFN-I responses by extracting nuclear DNA from dying cells via nucleocytosis.Nat Commun2026https://conductscience.org/library/papers/41708603PubMed
41551435Magic bullets, magic shields, and antimicrobials in between.Pharm Sci Adv2023https://conductscience.org/library/papers/41551435PubMed
41550857Strategic Preparedness of Broad-Spectrum Antivirals for Rapid Response Towards Next Pandemics.Small Sci2026https://conductscience.org/library/papers/41550857PubMed
41535311Evaluation of the cardiopulmonary effects of repurposed COVID-19 therapeutics in healthy rats.Sci Rep2026https://conductscience.org/library/papers/41535311PubMed
40771916Degradation of IRAK4 for the treatment of lipopolysaccharide-induced acute lung injury in mice.Front Pharmacol2025https://conductscience.org/library/papers/40771916PubMed
40665189Nasal inhalation of antiviral microparticulate powders to target early infection of upper airways.Drug Deliv Transl Res2026https://conductscience.org/library/papers/40665189PubMed
40615618The PRINCIPLE randomised controlled open label platform trial of hydroxychloroquine for treating COVID19 in community based patients at high risk.Sci Rep2025https://conductscience.org/library/papers/40615618PubMed
40535766Antimalarial compounds exhibit variant- and cell-type-specific activity against SARS-CoV-2 isolated in Panama.Front Pharmacol2025https://conductscience.org/library/papers/40535766PubMed
40476966[Recommendations for rheumatologists on pharmacological management during the COVID-19 health emergency: Expert group opinion].Rev Colomb Reumatol2021https://conductscience.org/library/papers/40476966PubMed
40476913A review on the immunomodulatory properties of functional nutraceuticals as dietary interventions for children to combat COVID-19 related infections.Food Prod Process Nutr2023https://conductscience.org/library/papers/40476913PubMed
40289186Hydroxychloroquine use during the first COVID-19 wave: a case study highlighting the urgent need to enhance research practices within the publication ecosystem.Arch Public Health2025https://conductscience.org/library/papers/40289186PubMed
40161134Safety of Hydroxychloroquine for COVID-19 Prophylaxis in Healthcare Workers: A Cross-Sectional Study.Cureus2025https://conductscience.org/library/papers/40161134PubMed
40122800A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization.Chin Med2025https://conductscience.org/library/papers/40122800PubMed
40074774Malabaricone C isolated from edible plants as a potential inhibitor of SARS-CoV-2 infection.Sci Rep2025https://conductscience.org/library/papers/40074774PubMed
40035964Low dose of hydroxychloroquine is associated with reduced COVID-19 mortality: a multicenter study in China.Front Med2025https://conductscience.org/library/papers/40035964PubMed
40007183Exploring Quinoline Derivatives: Their Antimalarial Efficacy and Structural Features.Med Chem2025https://conductscience.org/library/papers/40007183PubMed
39896318Exploration of innovative drug repurposing strategies for combating human protozoan diseases: Advances, challenges, and opportunities.J Pharm Anal2025https://conductscience.org/library/papers/39896318PubMed

See all 1,394 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Drugs8

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
COLCHICINECHEMBL107Results1https://conductscience.org/library/drugs/CHEMBL107ChEMBL
ROSUVASTATINCHEMBL1496Results1https://conductscience.org/library/drugs/CHEMBL1496ChEMBL
HYDROXYCHLOROQUINECHEMBL1535Results1https://conductscience.org/library/drugs/CHEMBL1535ChEMBL
EMTRICITABINE, (+/-)-CHEMBL161381Results1https://conductscience.org/library/drugs/CHEMBL161381ChEMBL
BROMHEXINECHEMBL253376Results1https://conductscience.org/library/drugs/CHEMBL253376ChEMBL
TENOFOVIRCHEMBL3989702Results1https://conductscience.org/library/drugs/CHEMBL3989702ChEMBL
CHLOROQUINECHEMBL76Results1https://conductscience.org/library/drugs/CHEMBL76ChEMBL
EMTRICITABINECHEMBL885Results1https://conductscience.org/library/drugs/CHEMBL885ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32150618

GET https://conductscience.org/api/papers/v1/32150618/cited_by?page=2